Advertisement

Development of a Dosage Form of the New Antitumor Antibiotic Olivamide

  • A. N. TevyashovaEmail author
  • E. N. Bychkova
  • L. G. Dezhenkova
  • A. E. Shchekotikhin
DRUG SYNTHESIS METHODS AND MANUFACTURING TECHNOLOGY

Methods for selective chemical modification of the antitumor antibiotic olivomycin A(OA) were developed at GINA. The compound olivamide with advantages over starting OA was selected from series of OA analogs. The goal of the present work was to develop a dosage form of the antitumor semi-synthetic antibiotic olivamide that guaranteed the stability and high specific activity of olivamide drug substance and was designed for further comprehensive preclinical studies.

Keywords

olivamide dosage form antiproliferative activity stability 

References

  1. 1.
    C. Mendez, J. Gonzalez-Sabin, F. Moris, and J. A. Salas, Planta Med., 81, 1326 – 1338 (2015).CrossRefGoogle Scholar
  2. 2.
    J. Gonzalez-Sabin and F. Moris, Biochem. Pharmacol., 2, 1 – 3 (2013).Google Scholar
  3. 3.
    G. F. Gause (ed.), Handbook of Experimental Pharmacology, Springer-Verlag Berlin, Heidelberg, New York (1975), pp. 615 – 622.Google Scholar
  4. 4.
    A. N. Tevyashova, Khim.-farm. Zh., 50(7), 3 – 8 (2016); Pharm. Chem. J., 50(7), 425 – 430 (2016).Google Scholar
  5. 5.
    A. N. Tevyashova, A. A. Shtil, E. N. Olsufyeva, et al., Bioorg. Med. Chem., 19, 7387 – 7393 (2011).CrossRefGoogle Scholar
  6. 6.
    G. Crini, Chem. Rev., 114(21), 10940 – 10975 (2014).CrossRefGoogle Scholar
  7. 7.
    B. Gidwani and A. Vyas, BioMed. Res. Int., 2015, 198268, 1 – 15 (2015).Google Scholar
  8. 8.
    H. M. Treshalina, V. I. Romanenko, D. N. Kaluzhny, et al., Eur. J. Pharm. Sci., 109, 631 – 637 (2017).CrossRefGoogle Scholar
  9. 9.
    O. Yu. Arshinova, E. V. Sanarova, A. V. Lantsova, and N. A. Oborotova, Pharm. Chem. J., 46(4), 228 – 233 (2012).CrossRefGoogle Scholar
  10. 10.
    H. R. Patel, R. P. Patel, and M. M. Patel, Int. J. PharmTech Res., 1(2), 299 – 303 (2009).Google Scholar
  11. 11.
    A. N. Mironov (ed.), Handbook for Preclinical Drug Studies [in Russian], Vol. 1, Grif i K, Moscow (2012), pp. 13 – 24.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • A. N. Tevyashova
    • 1
    • 2
    Email author
  • E. N. Bychkova
    • 1
  • L. G. Dezhenkova
    • 1
  • A. E. Shchekotikhin
    • 1
    • 2
  1. 1.G. F. Gause Institute of New Antibiotics (GINA)MoscowRussia
  2. 2.D. Mendeleev University of Chemical Technology of RussiaMoscowRussia

Personalised recommendations